

## Special Issue

# Integrating Immunotherapy, Novel Agents, and Their Combinations with Standard Treatments in the Management of Head and Neck Cancers

### Message from the Guest Editors

We are pleased to invite you to contribute to this Special Issue on the biology, rationale, and preclinical and clinical evidence on the optimum treatment combination of immunotherapy and novel agents with radiotherapy and/or chemotherapy to improve the treatment outcomes in head and neck cancers. We welcome high-quality review and original research articles covering basic, translational, and clinical studies related to these areas in head and neck cancers.

- head and neck cancer
- oropharyngeal cancer
- chemotherapy
- immunotherapy
- biomarker
- targeted therapies
- checkpoint inhibitor

---

### Guest Editors

Prof. Dr. Jan B. Vermorken

Dr. Petr Szturz

Prof. Dr. Kevin Harrington

Dr. Laurent Muller

---

### Deadline for manuscript submissions

31 March 2027



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.8**  
**CiteScore 9.0**  
**Indexed in PubMed**



[mdpi.com/si/272873](https://mdpi.com/si/272873)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)